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Dear Editor,

rights of an individual when registering into a
clinical trial must trickle at all levels of our society
if one wants to help humanity. Clinical trial is an
area which still needs powerful media campaign
which should focus on both the pros and cons.
The individual has to be given the advantage of
making decision by himself/herselfand not
through the research assistants who lure them in
order to gain financial benefits.

Pakistan with its teeming population and
economical and security setbacks cannot turn
away from the escalating health issues which are
important indicators for the development of a
nation. Clinical research has shown tremendous
growth in the past few years. The clinical trial,
which is the process of evaluation of drug safety
and its potential benefits[1] is increasingly a point
of interest by both multinational and national
pharmaceutical companies. This business has
progressed significantly in the past few years.[2]
The drug companies are making due efforts in
order to gain maximum benefits from this
progressing field in terms of business.[3] This has
resulted in some negativism. The three Cs of
Convince, Confuse and Corrupt of Chandra
Gulhati very truly project the current situation. I
will go through some points which I observe,
regarding the clinical trials in our country.

Also, the appointment of the research assistants
which are mostly medical students or the young
medical graduates is a major issue. They are not
aware of the significance of the trials nor are they
trained in terms of the International Conference
on Harmonization and Good Clinical Practice
Guidelines (ICH GCP guidelines). This accounts
for one of the reasons of high dropout rates
compared to the developed countries. The
assistants must know their rights and more
importantly the rights of the participants. The
pharmaceutical companies must set a point of
training all the individuals whom they hire as
research assistants. In most cases, the research
assistants are working as coordinators, clinical
research associate (CRA) and monitors, which is
one of the reasons of the mismanagement of the
data mostly seen in studies. The saturation in the
USA has resulted in the shifting of these trials to
South-East Asia mainly because of the good
enrollment rates due to low literacy, poverty and
large population. The increasing national drug
industry growth compare to the multinationals[4]
has not been good in terms of protecting the
ethical rights of the individual because they are
more concern for meeting their timelines and
patient enrollments not paying due attention to
the ethical chapter which is of pivotal importance.
By formulating necessary guidelines, we can

The patient enrollment was the first to seek
attention, as the pharmaceutical companies has
to enroll patients for their clinical trials; they visit
the areas which have low literacy rate, low
average household income and less knowledge
about the rights of the study participant. The
reason for this is because the companies are
striving for meeting their timelines, smooth patient
enrollments and low dropouts. The low literacy
rate makes the individuals unable to understand
the rationale of the trial and also if it does, they
can easily be confused. The consent forms which
if used are not explaining the core essence of the
trials, and are not translated. The forms are
grossly inadequate. There is a significant media
and literature scarcity for the people to know
about their rights. Ideally, the knowledge of the
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optimistically produce refined research assistants
which will be of benefit for clinical trials and
medical research.

its acceptance from the grass root level and the
young graduates and medical students can
provide us the necessary spice needed. Ethics
must not be limited to obtaining ERC approval. It
must diffuse into all aspects of the medical
profession.
Few
institutions
have
their
independent ethics setup which is working
effectively but we find chaos at the government
hospitals.

Furthermore, there should be proper patient
education before the enrollment process. They
should be given time and materials which should
include necessary information regarding the
efficacy, side effects and adverse effects of the
drug simply written in both English and Urdu. The
drop out from the study is mainly due to lack of
proper description of the study to participants.
Soon, individuals will lose faith in the doctors and
there will be no enrollments if this issue is not
addressed. The need for the availability of
platform for improving legal protection in
particular, providing protection to test data is
paramount. This is of the reason because
companies invest in countries where there are
laws for the protection of the study participants. A
very relevant example is of Jordan which has
shown increase in both research and
development and also the exponential growth of
the pharmaceutical industries due to the
implementation of these reforms.[2] Although there
are number of trials going on in the country, we
find very few full filling the standards.

Despite these, I appreciate the efforts being taken
by people at different levels for the progress of
clinical trial and ethics, but there is much more
which can be done and we are very optimistic that
in the near future, this will improve.
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Ethics is not a new chapter in our part of the
world. For the past few years, it has emerged as
an essential constituent for every institution
carrying out research.[5] Ethical approval is now
an integral essence to have international
collaborations and for obtaining funding.
However, there are some impurities mixing in it as
time passes. Although it has some very significant
positivism after its implementation the need to
safeguard it and to make a check on it is also
important. To begin with, the drug companies are
approaching different institutions for an easy
ethical approval to get their trial started and to
add on to it, there are also some incentives
getting into play in this drama. This has shown
some serious upsets in terms of quality. The
formation of Ethical Review Boards is a very bold
and a much needed step taken from our part of
the world. Educating the masses, including the
medical professionals must also be considered.
For a start of a successful program, it must have
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